BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 12, 2021
View Archived Issues
HepaRegeniX initiates first-in-human trial of HRX-0215
Read More
China Pharmaceutical University targets WDR5/MLL1 interaction with DDO-2213
Read More
GentiBio closes Series A financing to advance its pipeline of engineered Treg therapies
Read More
First patient dosed in phase I study of AVA-6000
Read More
IN8bio completes dosing of first cohort in phase I study of INB-100
Read More
Janssen describes mutant FimH compositions
Read More
Positive interim analysis data from phase II/III study of plonmarlimab in severe COVID-19
Read More
Jiangsu Hengrui Medicine and collaborators patent antibacterials
Read More
New PTPN11 inhibitors discovered at Betta Pharmaceuticals
Read More
Nuvation Bio identifies new adenosine A2a receptor antagonists
Read More
SAB-185 potently neutralizes delta and lambda SARS-CoV-2 variants in nonclinical studies
Read More
Oxford Vacmedix receives approval for its first-in-human study of OVM-200 cancer vaccine
Read More
Lynk initiates dosing in phase I study of its triple-kinase inhibitor LNK-01002
Read More
RemeGen completes phase II study of telitacicept in IgAN
Read More
FDA clears IND for XeriSol levothyroxine subcutaneous injection
Read More
Imatinib preserves Beta-cell function in subjects with type 1 diabetes
Read More
Cali Biosciences initiates MERIT-1 study of long-acting ropivacaine for postoperative pain
Read More
Further data from phase I study of UV-1 in metastatic melanoma
Read More
JadiCell shows superior neurogenesis induction in model of viral-induced cognitive dysfunction
Read More
Algernon Pharmaceuticals announces SCLC research program for ifenprodil
Read More
Enrollment ongoing in phase II studies of ABBV-154
Read More
Marker of neuroaxonal injury is also a marker of worse outcomes in COVID-19 patients
Read More